Drug Profile
Argatroban - Mitsubishi Chemical
Alternative Names: Acova; Arganova; Argatra; Argipidine; Da Bei; DK 7419; Exembol; GN 1600; MCI-9038; MD 805; Novastan; OM 805; SlonnonLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Mitsubishi Chemical
- Developer Correvio Pharma; Daiichi Sankyo Company; Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Europe; Novartis; University of Texas Health Science Center at Houston
- Class Anti-ischaemics; Anticoagulants; Antithrombotics; Carboxylic acids; Imines; Ischaemic heart disorder therapies; Pipecolic acids; Piperidines; Quinolines; Small molecules; Sulfones; Vascular disorder therapies
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Arterial thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral arterial occlusive disorders; Stroke
- Registered Intracranial thrombosis
- Discontinued Myocardial infarction; Unstable angina pectoris
Most Recent Events
- 08 Apr 2021 Discontinued - Phase-II for Stroke (Combination therapy) in United Kingdom (IV) (EudraCT2012-002319-25)
- 08 Apr 2021 Discontinued - Phase-II for Stroke (Combination therapy) in USA (IV) (NCT01464788)
- 01 Mar 2021 Daiichi Sankyo Company plans to transfer rights of Slonnon to Alfresa Pharma by December 2021